| |
|
|
|
|
| Slide Lecture Programs |
| 2006 Core Curriculum |
| Contemporary Management of Myocardial Ischemia |
May 17, 2006
|
| V: |
New Therapeutic Options for Chronic Stable Angina |
Slide 56 |
|
Download PowerPoint
|
MARISA: Summary
- Ranolazine SR at doses of 500 mg bid, 1000 mg bid, and 1500 mg bid demonstrated positive clinical effects for all outcome variables. For the primary outcome variable of increased exercise treadmill time at trough, all ranolazine doses were significantly better than placebo. Each ranolazine dose increased the time to onset of angina and time to 1 mm ST depression at trough vs placebo.
- Ranolazine SR exerted these positive effects without negatively affecting heart rate or blood pressure.
- There were no differences in adverse effects between placebo and the 500-mg bid dose. Most discontinuations in the ranolazine SR group occurred at the highest dose.
- There was a slight treatment-related prolongation of the QTc interval for all 3 doses of ranolazine SR compared with placebo. Mean differences vs placebo were 6, 7, and 11 milliseconds at trough and 5, 6, and 14 milliseconds at peak for the ranolazine 500 mg bid, 1000 mg bid, and 1500 mg bid treatments, respectively. However, no patient discontinued because of QTc prolongation.
|
|
|
Resources
